U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07136012) titled 'OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events' on Aug. 18.
Brief Summary: The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).
Study Start Date: Sept. 19
Study Type: INTERVENTIONAL
Condition:
Cardiovascular Disease
Intervention:
DRUG: Olpasiran
Olpasiran will be administered via SC injection....